The EMBRACE phase 2a study will investigate the potential of Gamifant® (emapalumab) in treating a subgroup of sepsis patients driven by the IDS endotype and absence of sepsis-induced immunoparalysis.

Sobi® (STO: SOBI), today announced a research collaboration involving a new Phase 2a clinical trial for Gamifant® (emapalumab) for the potential treatment of interferon-gamma (IFNγ)-driven sepsis (IDS ...

“Exciting” data were presented on emapalumab in the treatment of refractory macrophage activation syndrome (MAS) in patients with sJIA/Still disease. And the FDA approved three new drugs for JIA.

The US Food and Drug Administration has accepted Sobi’s supplemental biologics licence application for Gamifant ...

Switzerland’s Novimmune has filed its rare disease drug emapalumab in Europe, days after it sealed a deal selling rights to Sweden’s Sobi. The biotech, based in Geneva and Basel, has filed for ...

The EMBRACE phase 2a study will investigate the potential of Gamifant® (emapalumab) in treating a subgroup of sepsis patients driven by the IDS endotype and absence of sepsis-induced immunoparalysis.